Insulet's impressive growth with its Omnipod system, robust 2024 results, and surging valuation make it attractive. See more ...

Insulet Corporation (NASDAQ:PODD) reported fourth-quarter adjusted EPS of $1.15, down from $1.40 a year ago but beating the ...

Shares of Insulet Corp. PODD slid 1.90% to $282.80 Friday, on what proved to be an all-around dismal trading session for the ...

Insulin delivery company Insulet Corporation (NASDAQ:PODD) reported Q4 CY2024 results , with sales up 17.2% year on year to ...

Van ECK Associates Corp lessened its stake in Insulet Co. (NASDAQ:PODD – Free Report) by 2.1% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission.

Citi raised the firm’s price target on Insulet (PODD) to $355 from $310 and keeps a Buy rating on the shares. The company’s Q4 delivery was ...

Morgan Stanley raised the firm’s price target on Insulet (PODD) to $325 from $317 and keeps an Overweight rating on the shares following a ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Insulet reported a higher-than-expected profit in the fourth quarter on Thursday, driven by strong demand for its wearable insulin pumps. The company produces and sells Omnipod, an automated insulin ...

Insulet (PODD) delivered earnings and revenue surprises of 9.52% and 2.73%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

CIBC Asset Management Inc increased its position in shares of Insulet Co. (NASDAQ:PODD – Free Report) by 4.7% in the 4th ...